Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Next Previous
X
Search
Trial Profile

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EURTAC

    • Most Recent Events

    • 23 Mar 2018 Results (n=1312) assessing the value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer using data of patients those with either EGFR mutation exon 19 deletion or exon 21 L858R mutations from five phase III randomized trials EURTAC, IPASS, ENSURE, LUX-Lung 3, and LUX-Lung 6, published in the Journal of Thoracic Oncology.
    • 18 Oct 2017 Results assessing Overall survival Adjusting for Post-Progression Treatment Crossover in three phase III trials (EURTAC, ENSURE and OPTIMAL), presented at the 18th World Conference on Lung Cancer
    • 02 Jun 2015 Results from a meta-analysis of 6 trials showing impact on overall survival in patients with EGFR mutations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top